Trazpiroben clinical trials
Also written TAK-906.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses trazpiroben is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses trazpiroben is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic GastroparesisCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT03544229Written as TAK-906 Maleate
- Bioavailability and Food Effect Study of Two Formulations of TAK-906WithdrawnPhase 1TakedaNCT04831502Written as TAK-906
- Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male ParticipantsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT04454918Written as TAK-906 Oral Capsule
- A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult ParticipantsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT03849690Written as TAK-906
- Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male ParticipantsCompletedPhase 1TakedaNCT03237156Written as TAK-906
- A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)CompletedPhase 2Millennium Pharmaceuticals, Inc.NCT03268941Written as TAK-906 Maleate
- A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult ParticipantsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT04121078Written as TAK-906
- A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy ParticipantsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT03161405Written as TAK-906 Maleate
Codes
What other systems call trazpiroben · ClinicalTrials.gg INT001773
- MeSH (NLM) C000720755trazpirobenOne source NLM
- UNII (FDA) FH87H57Q4YTRAZPIROBENConfirmed FDA, NLM, Wikidata
- Wikidata Q112112717trazpirobenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171664TrazpirobenOne source FDA
- DrugBank DB18794One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720755 | trazpiroben | One source NLM |
| UNII (FDA) | FH87H57Q4Y | TRAZPIROBEN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q112112717 | trazpiroben | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171664 | Trazpiroben | One source FDA |
| DrugBank | DB18794 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.